Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Jan;36(1):214–216. doi: 10.1128/aac.36.1.214

In vitro drug combination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil with anti-human immunodeficiency virus or anticancer nucleosides.

H Machida 1, N Ashida 1, T Ikeda 1, S Sakata 1, M Baba 1, S Shigeta 1
PMCID: PMC189263  PMID: 1317147

Abstract

1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and E-5-(2-bromovinyl)uracil, a metabolite of BV-araU, did not affect either the anti-human immunodeficiency virus activity or the cytotoxicity of azidothymidine in MT-4 and MOLT-4 cells. Similarly, the bromovinyl compounds did not affect the in vitro antitumor activities of arabinosylcytosine, 5-fluorouracil, and 5-fluoro-2'-deoxyuridine. The anti-varicella-zoster virus activity of BV-araU was not influenced by azidothymidine, 2',3'-didehydro-2',3'-dideoxythymidine, or arabinosylcytosine, whereas relatively high concentrations of fluorinated antitumor agents enhanced the anti-varicella-zoster virus activity.

Full text

PDF
214

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baba M., Pauwels R., Herdewijn P., De Clercq E., Desmyter J., Vandeputte M. Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun. 1987 Jan 15;142(1):128–134. doi: 10.1016/0006-291x(87)90460-8. [DOI] [PubMed] [Google Scholar]
  2. Colebunders R., Mann J. M., Francis H., Bila K., Izaley L., Ilwaya M., Kakonde N., Quinn T. C., Curran J. W., Piot P. Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection. J Infect Dis. 1988 Feb;157(2):314–318. doi: 10.1093/infdis/157.2.314. [DOI] [PubMed] [Google Scholar]
  3. Desgranges C., Razaka G., De Clercq E., Herdewijn P., Balzarini J., Drouillet F., Bricaud H. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 1986 Mar;46(3):1094–1101. [PubMed] [Google Scholar]
  4. Hamamoto Y., Nakashima H., Matsui T., Matsuda A., Ueda T., Yamamoto N. Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother. 1987 Jun;31(6):907–910. doi: 10.1128/aac.31.6.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hiraoka A., Masaoka T., Nagai K., Horiuchi A., Kanamaru A., Niimura M., Hamada T., Takahashi M. Clinical effect of BV-araU on varicella-zoster virus infection in immunocompromised patients with haematological malignancies. J Antimicrob Chemother. 1991 Mar;27(3):361–367. doi: 10.1093/jac/27.3.361. [DOI] [PubMed] [Google Scholar]
  6. Lin T. S., Schinazi R. F., Prusoff W. H. Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol. 1987 Sep 1;36(17):2713–2718. doi: 10.1016/0006-2952(87)90253-x. [DOI] [PubMed] [Google Scholar]
  7. Machida H. Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleoside analogs. Antimicrob Agents Chemother. 1986 Mar;29(3):524–526. doi: 10.1128/aac.29.3.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Machida H., Nishitani M. Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir. Microbiol Immunol. 1990;34(4):407–411. doi: 10.1111/j.1348-0421.1990.tb01023.x. [DOI] [PubMed] [Google Scholar]
  9. Machida H., Nishitani M., Suzutani T., Hayashi K. Different antiviral potencies of BV-araU and related nucleoside analogues against herpes simplex virus type 1 in human cell lines and Vero cells. Microbiol Immunol. 1991;35(11):963–973. doi: 10.1111/j.1348-0421.1991.tb01618.x. [DOI] [PubMed] [Google Scholar]
  10. Machida H., Sakata S., Kuninaka A., Yoshino H. Antiherpesviral and anticellular effects of 1-beta-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracils. Antimicrob Agents Chemother. 1981 Jul;20(1):47–52. doi: 10.1128/aac.20.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mazur M. H., Dolin R. Herpes zoster at the NIH: a 20 year experience. Am J Med. 1978 Nov;65(5):738–744. doi: 10.1016/0002-9343(78)90791-x. [DOI] [PubMed] [Google Scholar]
  12. Niimura M. A double-blind clinical study in patients with herpes zoster to establish YN-72 (Brovavir) dose. Adv Exp Med Biol. 1990;278:267–275. doi: 10.1007/978-1-4684-5853-4_27. [DOI] [PubMed] [Google Scholar]
  13. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods. 1988 Aug;20(4):309–321. doi: 10.1016/0166-0934(88)90134-6. [DOI] [PubMed] [Google Scholar]
  14. Suzutani T., Machida H., Sakuma T., Azuma M. Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1988 Oct;32(10):1547–1551. doi: 10.1128/aac.32.10.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES